Zeta

LEF1 Recombinant Rabbit Monoclonal Antibody (ZR336)

View all (55) LEF1 antibodies

Promotion

View available promotion(s)

Promo code: {{promo.promoCode}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}

Datasheet
Protocols
Questions & Answers
Datasheet
Protocols
Questions & Answers

Product Details

Z2642RP

Applications
Tested Dilution
Publications

Immunohistochemistry (Paraffin) (IHC (P))

Ready-to-use 150-200 µL
-
Product Specifications

Species Reactivity

Human

Host/Isotype

Rabbit / IgG

Expression System

CHO cells

Class

Recombinant Monoclonal

Type

Antibody

Clone

ZR336

Immunogen

Fragment (around aa 100-200) of human LEF1 protein
View immunogen

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Purification

Protein A

Storage buffer

tris with BSA, NP-40

Contains

<0.1% sodium azide

Storage conditions

4°C

Shipping conditions

Ambient (domestic); Wet ice (international)

Product Specific Information

This product is diluted and in a ready-to-use formulation.

A recommended positive control tissue for this product is Tonsil (B cells), however positive controls are not limited to this tissue type.

The primary antibody is intended for laboratory professional use in the detection of the corresponding protein in formalin-fixed, paraffin-embedded tissue stained in manual qualitative immunohistochemistry (IHC) testing. This antibody is intended to be used after the primary diagnosis of tumor has been made by conventional histopathology using non-immunological histochemical stains.

Lymphoid Enhancing Factor 1 (LEF1) is a transcription factor that belongs to the TCF/LEF family. LEF1 participates as a regulator in Wnt signaling pathways. LEF1 is an important factor in lymphopoiesis and is expressed normally in T and pro-B cells but not expressed in mature B cells. Strong nuclear expression of LEF1 has been observed in majority of chronic lymphocytic leukemia/small lymphocytic lymphoma cases and LEF1 is not detected in other small B cell lymphomas. Anti-LEF1 may be used as an aid for differentiation of chronic lymphocytic leukemia/small lymphocytic lymphoma from other small B cell lymphomas.

Antibody is used with formalin-fixed and paraffin-embedded sections. Pretreatment of deparaffinized tissue with heat-induced epitope retrieval or enzymatic retrieval is recommended. In general, immunohistochemical (IHC) staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody (link antibody), an enzyme complex and a chromogenic substrate with interposed washing steps. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.

A positive tissue control must be run with every staining procedure performed. This tissue may contain both positive and negative staining cells or tissue components and serve as both the positive and negative control tissue. External Positive control materials should be fresh autopsy/biopsy/surgical specimens fixed, processed and embedded as soon as possible in the same manner as the patient sample (s). Positive tissue controls are indicative of correctly prepared tissues and proper staining methods. The tissues used for the external positive control materials should be selected from the patient specimens with well-characterized low levels of the positive target activity that gives weak positive staining. The low level of positivity for external positive controls is designed to ensure detection of subtle changes in the primary antibody sensitivity from instability or problems with the staining methodology. A tissue with weak positive staining is more suitable for optimal quality control and for detecting minor levels of reagent degradation.

Internal or external negative control tissue may be used depending on the guidelines and policies that govern the organization to which the end user belongs to. The variety of cell types present in many tissue sections offers internal negative control sites, but this should be verified by the user. The components that do not stain should demonstrate the absence of specific staining, and provide an indication of non-specific background staining. If specific staining occurs in the negative tissue control sites, results with the patient specimens must be considered invalid.

Target Information

This gene encodes a transcription factor belonging to a family of proteins that share homology with the high mobility group protein-1. The protein encoded by this gene can bind to a functionally important site in the T-cell receptor-alpha enhancer, thereby conferring maximal enhancer activity. This transcription factor is involved in the Wnt signaling pathway, and it may function in hair cell differentiation and follicle morphogenesis. Mutations in this gene have been found in somatic sebaceous tumors. This gene has also been linked to other cancers, including androgen-independent prostate cancer. Alternative splicing results in multiple transcript variants.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

References (0)

Have you cited this product in a publication?
Let us know so we can reference it here.
Cite this product

Bioinformatics

Protein Aliases: DKFZp586H0919; FLJ46390; HGNC:6551; HMG Binding Domain; LEF-1; Lymphoid enhancer-binding factor 1; OTTHUMP00000219736; OTTHUMP00000219737; T cell-specific transcription factor 1-alpha; TCF1-alpha

View more View less

Gene Aliases: LEF-1; LEF1; TCF10; TCF1ALPHA; TCF7L3

View more View less

UniProt ID: (Human) Q9UJU2

View more View less

Entrez Gene ID: (Human) 51176

View more View less

Function(s)
RNA polymerase II regulatory region sequence-specific DNA binding RNA polymerase II core promoter proximal region sequence-specific DNA binding transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding DNA binding chromatin binding transcription factor activity, sequence-specific DNA binding transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding protein binding beta-catenin binding transcription factor binding DNA binding, bending estrogen receptor activity estrogen receptor binding enhancer binding histone binding histone deacetylase binding cysteine-type endopeptidase inhibitor activity involved in apoptotic process sequence-specific DNA binding transcription regulatory region DNA binding gamma-catenin binding armadillo repeat domain binding C2H2 zinc finger domain binding
Process(es)
negative regulation of transcription from RNA polymerase II promoter patterning of blood vessels osteoblast differentiation neural crest cell migration somitogenesis kidney development epithelial to mesenchymal transition sprouting angiogenesis transcription from RNA polymerase II promoter Wnt signaling pathway, calcium modulating pathway positive regulation of cell proliferation response to lithium ion positive regulation of gene expression positive regulation of epithelial to mesenchymal transition Wnt signaling pathway regulation of striated muscle tissue development dentate gyrus development hypothalamus development forebrain radial glial cell differentiation forebrain neuroblast division forebrain neuron differentiation formation of radial glial scaffolds regulation of cell-cell adhesion neutrophil differentiation positive regulation of cell growth embryonic limb morphogenesis positive regulation of cell migration BMP signaling pathway positive regulation of granulocyte differentiation mammary gland development organ regeneration negative regulation of interleukin-13 production negative regulation of interleukin-4 production negative regulation of interleukin-5 production T cell receptor V(D)J recombination B cell proliferation odontogenesis of dentin-containing tooth negative regulation of apoptotic process negative regulation of cysteine-type endopeptidase activity involved in apoptotic process negative regulation of DNA binding steroid hormone mediated signaling pathway tongue development skin development positive regulation by host of viral transcription histone H3 acetylation histone H4 acetylation T-helper 1 cell differentiation negative regulation of striated muscle tissue development negative regulation of transcription, DNA-templated positive regulation of transcription, DNA-templated positive regulation of transcription from RNA polymerase II promoter alpha-beta T cell differentiation eye pigmentation paraxial mesoderm formation muscle fiber development sensory perception of taste palate development anatomical structure regression canonical Wnt signaling pathway face morphogenesis cell chemotaxis apoptotic process involved in morphogenesis chorio-allantoic fusion trachea gland development cellular response to cytokine stimulus cellular response to interleukin-4 positive regulation of cell proliferation in bone marrow negative regulation of apoptotic process in bone marrow odontoblast differentiation negative regulation of estrogen receptor binding negative regulation of canonical Wnt signaling pathway apoptotic process involved in patterning of blood vessels beta-catenin-TCF complex assembly
guarantee_icon

Performance Guarantee

If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*

Learn more
help_icon

We're here to help

Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.

Contact tech support